Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21265982 | 0.87 | NOTUM (0.42) | — | |
| SCHEMBL2549674 | 0.82 | MEN1 (0.39) | MEN1KMT2AGRM2ADAMTS5MAPK1 | |
| SCHEMBL12458917 | 0.81 | KMT2A (0.42) | MEN1KMT2AGRM2ADAMTS5MAPK1 | |
| SCHEMBL14225445 | 0.79 | MEN1 (0.44) | MEN1KMT2AGRM2ADAMTS5MAPK1 | |
| SCHEMBL7425205 | 0.75 | SMYD3 (0.50) | MEN1KMT2AGRM2ADAMTS5MAPK1 | |
| SCHEMBL21089926 | 0.74 | — | — | |
| SCHEMBL21090068 | 0.74 | GABRA2 (0.33) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL26500903 | 0.73 | — | — | |
| SCHEMBL4891287 | 0.73 | MEN1 (0.44) | MEN1KMT2AGRM2ADAMTS5MAPK1 | |
| SCHEMBL30162824 | 0.72 | MEN1 (0.39) | MEN1KMT2AGRM2ADAMTS5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202799-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-20190175571-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202799-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | BRD4, BRPF3, BRD3 | MEN1 756/4885KMT2A 251/4885GRM2 3785/4885 |
| US-20190175571-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | BRD4, BRPF3, BRD3 | MEN1 712/4885KMT2A 139/4885GRM2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.